Diese Webseite verwendet Cookies

Diese Seite verwendet Cookies, um Ihnen dieses Angebot leicht zugänglich zu machen, Inhalte zu personalisieren, Ihre Zugriffe auf die Webseite zu analysieren und Ihnen ggf. personalisierte Angebote unterbreiten zu können. Hierzu kann es notwendig sein, dass die Informationen über Ihre Verwendung der Webseite an Partner weitergegeben werden. Diese führen die gesammelten Informationen möglicherweise mit weiteren Daten zusammen, die Sie an anderer Stelle bereitgestellt haben. Eine Weitergabe erfolgt dabei aber nur mit Ihrer Einwilligung und unter Beachtung der datenschutzrechtlichen Vorgaben. Weiterführende Informationen über die hier verwendeten Cookies erfahren Sie in den folgenden Erklärungen zu den jeweiligen Cookies.

Notwendige Cookies helfen dabei, Ihnen die Funktionen der Webseite zugängig zu machen, indem sie Grundfunktionen die zuletzt angesehen Wertpapiere und Ihre Entscheidung für oder gegen die Nutzung der jeweiligen Cookies speichert. Die Webseite wird ohne diese Cookies nicht so funktionieren, wie es geplant ist.

Name Anbieter Zweck Ablauf Typ Verantwortlicher
CookieConsent2111 Moneyspecial Um diese Cookiebar auszublenden. 1 Jahr http Infront Financial Technology GmbH
Die Cookie-Erklärung wurde das letzte Mal am 27.07.2020 von Infront Financial Technology GmbH aktualisiert.
Drucken



Advanced Biotech For Sustainability (AB4S) Coalition Unveils "The Molecule Manifesto," Pinpointing Four Key Pathways to a $1.1 Trillion Biotech Economy




Advanced Biotech For Sustainability (AB4S) Coalition Unveils "The Molecule Manifesto," Pinpointing Four Key Pathways to a $1.1 Trillion Biotech Economy


PR Newswire





BRUSSELS, March 17, 2026 /PRNewswire/ -- Today, Advanced Biotech for Sustainability (AB4S), a cross-sector coalition that's committed to unlocking the full environmental potential of advanced biotechnology, published its second annual report, "The Molecule Manifesto: Four Priority Molecule Families to Unlock Industrial Biotech Scale."  Following last year's quantification of a $1.1 trillion market opportunity, this new roadmap identifies the specific molecular "winners" ready for immediate commercial scale-up to meet global climate and supply chain goals.


Cradle

While AB4S' inaugural report established the economic case for biotechnology, the 2026 report shifts from theory to execution. After evaluating over 300 molecules across 40 chemical families, the coalition has identified four priority families, terpenes, peptides, non-catalytic proteins, and hydroxy acids, as the most viable near-term opportunities for biobased production. 

Key insights from the report include:

  • Terpenes and terpenoids represent a $7 to $12 billion market and the fastest path to commercial deployment. The fragrance and flavor industry already accepts bio-sourced terpenes at premium prices.
  • Bioactive peptides applications span from cosmetics and personal care to agriculture and food and represent a potential $2.2-3.4B market by 2030. The value proposition for these molecules is multifunctionality. Regulations are driving the need for innovation in novel bioactive peptides discovery for various applications and biotechnology offers cutting edge solutions for their production.
  • Functional proteins deliver performance through physical and biological function: foaming, gelling, emulsification, sweetness, bioactivity, that commodity nutrition proteins, like casein, cannot replicate. Precision fermentation offers the possibility to produce these proteins with high titers without animal agriculture, eliminating supply chain volatility, enabling novel functionality, positioning them as a major long-term market opportunity of $21-31B as adoption scales.
  • Hydroxy acids offer a different value proposition: integration into existing chemical infrastructure. These molecules can be produced via fermentation and then converted to high-volume derivatives using established chemical processing, leveraging existing facilities rather than requiring purpose-built biomanufacturing facilities. Excluding commodity citric/lactic acid, hydroxy acids present a potential $1.8-2B market opportunity.

To translate this report's prioritization into commercial reality, AB4S calls for greater collaboration and investment in terpenes, peptides, non-catalytic proteins, and hydroxy acids-alongside targeted infrastructure investment and cross-sector collaboration to move these four molecule families from pilot to full industrial scale.

"AI is already delivering impressive results for top innovators around the world, bringing new molecules to market faster and at lower cost than ever before," said Stef van Grieken, CEO of AB4S member Cradle, an AI-powered protein design platform. "Sustainable materials represent a significant growth opportunity, and the nexus is right here in Europe. With strong support for sustainable materials and biotech across the region, plus a world-class labor pool, leaders who embrace these insights can power new industries that will unlock impressive benefits across society."

To download the full report, visit: https://www.ab4s.org/2026

About Advanced Biotech for Sustainability (AB4S)
Founded in 2025, the Advanced Biotech for Sustainability (AB4S) is a coalition of industry-leading organizations from across the ecosystem (including incumbent, start-up, scale-up and non-profit) that are committed to unlocking the full potential of advanced biotechnology through thought leadership, actionable recommendations and cross-industry collaboration. AB4S currently comprises 8 founding members, including Arsenale Bioyards, Cradle, Darwin International, EIT Food, Evonik, Lallemand, L'Oréal, and ShakeUp Factory. For more information on the coalition or to support its mission, visit www.ab4s.org

Logo - https://mma.prnewswire.com/media/2846228/Cradle_Logo.jpg 

 





Cision View original content:https://www.prnewswire.co.uk/news-releases/advanced-biotech-for-sustainability-ab4s-coalition-unveils-the-molecule-manifesto-pinpointing-four-key-pathways-to-a-1-1-trillion-biotech-economy-302715300.html





PR Newswire

Zeit Meldung
17.03. PRN: CONEXPO-CON/AGG 2026: Lösungen von XCMG für a
17.03. PRN: Sequential™ beschafft 3,5 Millionen Dollar fü
17.03. PRN: Brandwatch Report Finds Only 25% of Marketers
17.03. PRN: IBM Completes Acquisition of Confluent, Makin
17.03. PRN: Nscale erwirbt American Intelligence & Power
17.03. PRN: TUMI präsentiert „Mediterranean Escape" - ein
17.03. PRN: Apertura Gene Therapy und Viralgen kündigen s
17.03. PRN: Endo Tools Therapeutics Receives FDA 510(k) C
17.03. PRN: Thunes bringt Stablecoin-Auszahlungen über Sw
17.03. PRN: Advanced Biotech For Sustainability (AB4S) Co
17.03. PRN: Lucid stellt seine kommende MidsizePlattform
17.03. PRN: European Parliament Hosts Conference on Globa
17.03. PRN: Le Clarence unter der Leitung von Andrea Capa
17.03. PRN: Kavalan Appoints Marussia Beverages UK as Sol
17.03. PRN: Mintos erweitert sein Angebot in Zusammenarbe
17.03. PRN: Mintos broadens its offering with regulated c
17.03. PRN: Starlight Investments gibt den Abschluss des
17.03. PRN: THE SEVEN DEADLY SINS: ORIGIN - JETZT FRÜHER
17.03. PRN: Bitmine Immersion Technologies (BMNR): ETH-Be
17.03. PRN: Sony Semiconductor Solutions bringt 4K-Bildse
17.03. PRN: Werk von Piramal Pharma Solutions im schottis
17.03. PRN: Viva Biotech Accelerates AI-Driven Drug Disco
17.03. PRN: Nscale und Microsoft kündigen Zusammenarbeit
16.03. PRN: Zentiva veröffentlicht Nachhaltigkeitsbericht
16.03. PRN: WEKA maximiert die Token -Produktion bei geri

Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de

Angebote der
Nutzungshinweise | Datenschutz | Impressum | Datenquellen: boerse-stuttgart.de,